Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)

Market Cap	12.82B -11.9%
Revenue (ttm)	9.36B -14.4%
Net Income	941.60M -13.1%
EPS	0.70 -13.1%
Shares Out	1.34B
PE Ratio	13.62
Forward PE	n/a
Dividend	0.30 (3.13%)
Ex-Dividend Date	n/a

Volume	9,639,245
Average Volume	11,743,613
Open	9.58
Previous Close	9.59
Day's Range	9.50 - 9.66
52-Week Range	9.50 - 11.80
Beta	0.30
RSI	30.92
Earnings Date	Apr 30, 2026

About SHA:600420

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and develops, produce, and sell of pharmaceutical products in China. The company offers nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granules, and c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 9,697
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600420

Financial Performance

In 2025, SHA:600420's revenue was 9.36 billion, a decrease of -14.39% compared to the previous year's 10.94 billion. Earnings were 941.60 million, a decrease of -13.11%.